Kayfanda

Odevixibat, the active ingredient in Kayfanda, is a Ileal bile acid transporter (IBAT) inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome, conditions characterized by cholestatic liver disease. GNH USA supplies Kayfanda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, adhering to stringent quality standards and providing full regulatory documentation to streamline import, distribution and clinical use across global markets.

Kayfanda (odevixibat) acts on the bile acid transport pathway to relieve itching in cholestatic liver disorders. - Pruritus associated with progressive familial intrahepatic cholestasis (PFIC): reduces itch intensity and improves quality of life. - Pruritus associated with Alagille syndrome: alleviates severe itching symptoms in affected patients. - Cholestasis treatment: lowers serum bile acid concentrations, addressing the underlying cause of pruritus.

Adverse reactions reported with Kayfanda are generally related to its impact on gastrointestinal function and metabolic processes.

Common Side Effects: - Diarrhea: frequent loose stools. - Abdominal pain: cramping or discomfort in the stomach area. - Nausea: feeling of sickness or urge to vomit.

Serious or Rare Side Effects: - Elevated liver enzymes: indicates potential liver injury. - Severe dehydration: due to excessive fluid loss from diarrhea. - Allergic reaction: rash, swelling, or difficulty breathing. - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain.

When prescribing Kayfanda, clinicians should consider several precautionary measures to ensure patient safety. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Assess hydration status: ensure adequate fluid intake to prevent dehydration. - Avoid use in patients with known hypersensitivity to odevixibat or excipients. - Use caution in severe renal impairment: adjust monitoring and consider risk‑benefit. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Kayfanda may interact with other medicines that affect bile acid metabolism or drug absorption.

Major Interactions (Avoid): - Bile acid sequestrants: can bind odevixibat and markedly reduce its absorption. - Strong CYP3A4 inducers: may decrease odevixibat plasma concentrations and efficacy. - Concomitant use with cholestyramine: interferes with drug bioavailability.

Moderate Interactions (Monitor Closely): - Antacids: may alter gastrointestinal pH and affect odevixibat absorption. - High‑fat meals: can modify the rate of drug uptake and require timing adjustments.